3results about How to "Effective therapeutic effect" patented technology

The application provides an adenosine co-crystal and a preparation method and application thereof, and belongs to the technical field of biological medicines.The adenosine co-crystal is formed by adenosine and ikar or nicotinamide according to a molar ratio of 1:0.2-16.9, and overcomes the problem of poor bioavailability of adenosine in the prior art.The adenosine co-crystal provided by the application has a significantly higher solubility compared with adenosine, can improve the blood drug concentration in vivo as a medicine to further play a more effective therapeutic role, can avoid the influence of the hydrophobicity of the stratum corneum to further improve the skin permeability of the product as a skin care product or a cosmetic product, and can improve the solubility of the effective component in the product to better play a hair growth effect as a hair growth product, and has wide application potential.The preparation method of the co-crystal has simple steps, high efficiency, low cost, and the advantages of being suitable for large-scale production.

This invention belongs to the field of biomedicine, specifically relating to siRNA that inhibits AR gene expression, comprising a sense strand and an antisense strand, wherein the sense strand and the antisense strand are at least partially anticomplementary to form a double-stranded region, and the sense strand or antisense strand consists of 19-25 nucleotides with blunt ends of complementary nucleotide sequences; or the antisense strand consists of 27 nucleotide sequences with overhangs. The siRNA of this invention can maintain long-term efficacy with a single dose, exhibiting good compliance in patients with chronic diseases such as androgenetic alopecia. Furthermore, it has lower off-target toxicity and fewer side effects compared to small molecule chemical drugs and hormone drugs.

The application discloses a group of antibodies specifically recognizing IgA1 with galactose deficiency and application thereof, and belongs to the technical field of antibodies. The main problem to be solved by the application is how to obtain anti-Gd-IgA1 antibodies with high specificity. In order to solve the above technical problem, the application provides antibodies or antigen binding fragments thereof, and the antibodies can be antibody B0020, antibody B0035 or antibody B0043. Compared with the existing antibody KM55, the obtained antibodies have the advantage of high affinity with antigens, and are expected to be more effectively used for diagnosis of IgA nephropathy, monitoring of treatment efficacy, judgment of prognosis and the like.